Is Halozyme Therapeutics Stock a Good Investment?
Halozyme Therapeutics Investment Advice | HALO |
- Examine Halozyme Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Halozyme Therapeutics' leadership team and their track record. Good management can help Halozyme Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Halozyme Therapeutics' business and its evolving consumer preferences.
- Compare Halozyme Therapeutics' performance and market position to its competitors. Analyze how Halozyme Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Halozyme Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Halozyme Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Halozyme Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Halozyme Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Halozyme Therapeutics Stock
Researching Halozyme Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003.
To determine if Halozyme Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Halozyme Therapeutics' research are outlined below:
| Halozyme Therapeutics generated a negative expected return over the last 90 days | |
| Halozyme Therapeutics has high historical volatility and very poor performance | |
| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Halozyme Therapeutics Stock Price Down 4.4 percent Heres What Happened |
Halozyme Therapeutics Quarterly Accounts Payable |
|
Halozyme Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Halozyme Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Halozyme Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Halozyme Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Halozyme Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2007-03-08 | 2006-12-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2006-05-10 | 2006-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2006-03-23 | 2005-12-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2005-11-11 | 2005-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2004-08-16 | 2004-06-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2020-05-11 | 2020-03-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2019-02-21 | 2018-12-31 | -0.03 | -0.01 | 0.02 | 66 | ||
2015-03-02 | 2014-12-31 | -0.06 | -0.04 | 0.02 | 33 |
Know Halozyme Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Halozyme Therapeutics' institutional investor refers to the entity that pools money to purchase Halozyme Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-06-30 | 2.2 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 2.1 M | Handelsbanken Fonder Ab | 2024-09-30 | 2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.9 M | Bank Of America Corp | 2024-06-30 | 1.8 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.8 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.8 M | Northern Trust Corp | 2024-09-30 | 1.7 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.6 M | Blackrock Inc | 2024-06-30 | 17.6 M | Vanguard Group Inc | 2024-09-30 | 12.9 M |
Halozyme Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.82 B.Market Cap |
|
Halozyme Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.33 | 0.35 | |
| Return On Capital Employed | 0.21 | 0.22 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 3.36 | 3.53 |
Determining Halozyme Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Halozyme Therapeutics is a good buy. For example, gross profit margin measures Halozyme Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Halozyme Therapeutics' profitability and make more informed investment decisions.
Evaluate Halozyme Therapeutics' management efficiency
Halozyme Therapeutics has return on total asset (ROA) of 0.1487 % which means that it generated a profit of $0.1487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.1183 %, meaning that it created $1.1183 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to grow to 0.35. Also, Return On Capital Employed is likely to grow to 0.22. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 21st of November 2024, Fixed Asset Turnover is likely to grow to 16.71, while Non Currrent Assets Other are likely to drop about 9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.64 | 0.40 | |
| Tangible Book Value Per Share | (6.11) | (5.80) | |
| Enterprise Value Over EBITDA | 13.84 | 14.54 | |
| Price Book Value Ratio | 58.18 | 55.27 | |
| Enterprise Value Multiple | 13.84 | 14.54 | |
| Price Fair Value | 58.18 | 55.27 | |
| Enterprise Value | 2 B | 2 B |
The decision-making processes within Halozyme Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.29 |
Basic technical analysis of Halozyme Stock
As of the 21st of November, Halozyme Therapeutics retains the Market Risk Adjusted Performance of (0.24), standard deviation of 3.65, and Risk Adjusted Performance of (0.07). Halozyme Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Halozyme Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Halozyme Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Halozyme Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Halozyme Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Halozyme Therapeutics' Outstanding Corporate Bonds
Halozyme Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Halozyme Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Halozyme bonds can be classified according to their maturity, which is the date when Halozyme Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View |
Understand Halozyme Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Halozyme Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (999.20) | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.33 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 28.41 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 3.25 | |||
| Skewness | (0.73) | |||
| Kurtosis | 6.16 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (999.20) | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.33 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 28.41 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 3.25 | |||
| Skewness | (0.73) | |||
| Kurtosis | 6.16 |
Consider Halozyme Therapeutics' intraday indicators
Halozyme Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Halozyme Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Halozyme Therapeutics Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 17th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 16th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Halozyme Stock media impact
Far too much social signal, news, headlines, and media speculation about Halozyme Therapeutics that are available to investors today. That information is available publicly through Halozyme media outlets and privately through word of mouth or via Halozyme internal channels. However, regardless of the origin, that massive amount of Halozyme data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Halozyme Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Halozyme Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Halozyme Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Halozyme Therapeutics alpha.
Halozyme Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Halozyme Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Halozyme Therapeutics Corporate Management
| Mark Esq | Senior Officer | Profile | |
| Kristin Schwartzbauer | Head Quality | Profile | |
| Gary Grote | Chief Officer | Profile | |
| Nicole LaBrosse | CFO Director | Profile | |
| MD MBA | Chief Officer | Profile | |
| Amy Fox | Senior Resources | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Halozyme Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.